Table 1 Baseline demographics and characteristics of eptinezumab-treated ≥ 50–< 75% and ≥ 75% migraine responders
Eptinezumab 100 mg | Eptinezumab 300 mg | Eptinezumab Pooled | ||||
PROMISE-1 (EM) | ≥ 50–< 75% N = 61 | ≥ 75% N = 49 | ≥ 50–< 75% N = 59 | ≥ 75% N = 66 | ≥ 50–< 75% N = 120 | ≥ 75% N = 115 |
Mean age, years (SD) | 40.5 (10.09) | 39.1 (12.18) | 40.1 (13.03) | 40.1 (11.21) | 40.3 (11.58) | 39.7 (11.59) |
Sex, n (%) | ||||||
Female | 47 (77.0%) | 39 (79.6%) | 52 (88.1%) | 57 (86.4%) | 99 (82.5%) | 96 (83.5%) |
Male | 14 (23.0%) | 10 (20.4%) | 7 (11.9%) | 9 (13.6%) | 21 (17.5%) | 19 (16.5%) |
Race, n (%) | ||||||
White | 53 (86.9%) | 43 (87.8%) | 52 (88.1%) | 58 (87.9%) | 105 (87.5%) | 101 (87.8%) |
Black or African American | 6 (9.8%) | 2 (4.1%) | 5 (8.5%) | 7 (10.6%) | 11 (9.2%) | 9 (7.8%) |
Other | 2 (3.3%) | 4 (8.2%) | 2 (3.4%) | 1 (1.5%) | 4 (3.3%) | 5 (4.3%) |
Mean (SD) BMI, kg/m2 | 29.5 (6.56) | 28.0 (7.48) | 27.4 (6.59) | 29.8 (7.28) | 28.4 (6.63) | 29.0 (7.39) |
Mean (SD) age at diagnosis, years | 23.4 (11.50) | 19.9 (9.24) | 22.7 (10.28) | 21.0 (9.39) | 23.1 (10.88) | 20.5 (9.30) |
Mean (SD) duration of migraine diagnosis, years | 17.0 (12.16) | 19.3 (10.99) | 17.4 (13.10) | 19.0 (11.22) | 17.2 (12.58) | 19.1 (11.07) |
Mean (SD) baseline migraine days | 8.3 (2.66) | 8.8 (2.85) | 9.0 (2.79) | 8.5 (2.86) | 8.7 (2.73) | 8.6 (2.84) |
Mean (SD) baseline headache days | 9.2 (2.77) | 10.0 (2.65) | 10.0 (2.74) | 10.4 (3.32) | 9.6 (2.77) | 10.3 (3.05) |
PROMISE-2 (CM) | ≥ 50–< 75% N = 110 | ≥ 75% N = 95 | ≥ 50–< 75% N = 99 | ≥ 75% N = 116 | ≥ 50–< 75% N = 209 | ≥ 75% N = 211 |
Mean age, years (SD) | 38.3 (11.37) | 43.9 (11.18) | 42.1 (10.95) | 41.1 (10.06) | 40.1 (11.31) | 42.3 (10.64) |
Sex, n (%) | ||||||
Female | 98 (89.1%) | 80 (84.2%) | 92 (92.9%) | 102 (87.9%) | 190 (90.9%) | 182 (86.3%) |
Male | 38.3 (11.37) | 15 (15.8%) | 7 (7.1%) | 14 (12.1%) | 19 (9.1%) | 29 (13.7%) |
Race, n (%) | ||||||
White | 106 (96.4%) | 90 (94.7%) | 91 (91.9%) | 108 (93.1%) | 197 (94.3%) | 198 (93.8%) |
Black or African American | 4 (3.6%) | 5 (5.3%) | 6 (6.1%) | 6 (5.2%) | 10 (4.8%) | 11 (5.2%) |
Other | 0 | 0 | 2 (2.0%) | 2 (1.7%) | 2 (1.0%) | 2 (0.9%) |
Mean (SD) BMI, kg/m2 | 25.4 (4.77) | 26.3 (4.11) | 25.9 (4.25) | 26.5 (4.87) | 25.6 (4.53) | 26.4 (4.53) |
Mean (SD) age at diagnosis, years | 20.7 (9.39) | 24.1 (10.13) | 22.0 (9.52) | 23.0 (9.43) | 21.3 (9.46) | 23.5 (9.74) |
Mean (SD) duration of migraine diagnosis, years | 17.7 (11.02) | 19.7 (12.43) | 20.1 (12.71) | 18.1 (11.25) | 18.8 (11.88) | 18.8 (11.80) |
Mean (SD) duration of chronic migraine, years | 10.4 (11.19) | 10.3 (12.30) | 13.2 (12.38) | 10.8 (11.01) | 11.7 (11.82) | 10.6 (11.58) |
Mean (SD) baseline migraine days | 16.1 (4.43) | 15.7 (4.18) | 15.5 (4.64) | 15.0 (4.42) | 15.8 (4.53) | 15.3 (4.32) |
Mean (SD) baseline headache days | 20.2 (3.01) | 19.6 (2.54) | 19.8 (3.09) | 20.0 (3.11) | 20.0 (3.05) | 19.8 (2.86) |
Medication-overuse headache diagnosis, n (%) | 46 (41.8%) | 38 (40.0%) | 47 (47.5%) | 44 (37.9%) | 93 (44.5%) | 82 (38.9%) |